

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 December 2022 (15.12.2022)



(10) International Publication Number
WO 2022/261623 A1

(51) International Patent Classification:

A61K 31/341 (2006.01) C07D 233/72 (2006.01)
A61K 31/4178 (2006.01) C07D 307/64 (2006.01)

(21) International Application Number:

PCT/US2022/072789

(22) International Filing Date:

07 June 2022 (07.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/208,268 08 June 2021 (08.06.2021) US

(71) Applicant: **FORESEE PHARMACEUTICALS CO., LTD.**; 17F., No. 3, Park St., Nankang District, Taipei City, 115 (TW).

(72) Inventors; and

(71) Applicants: **LI, Yuhua** [US/US]; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US). **CHIEN, Benjamin** [US/US]; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US).

(74) Agent: **HE, Ming** et al.; Ice Miller LLP, 1735 Market Street, Suite 3900, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: USE OF MMP INHIBITORS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME




FIG. 1A

(57) Abstract: Methods of treating acute respiratory distress syndrome (ARDS) by administration of a matrix metalloproteinase (MMP) inhibitor are described.

WO 2022/261623 A1